title: A case of antisynthetase syndrome in a rheumatoid arthritis patient with anti-PL-12 antibody following treatment with etanercept.
abstract: In our earlier study, we had reported the case of a patient with rheumatoid arthritis (RA), who had anti-Jo-1 antibodies. This patient had received etanercept (ETN) therapy for RA, after which she had developed overt polymyositis (PM). Although various autoimmune phenomena, including lupus-like diseases, vasculitides, or psoriatic skin lesions, are associated with antitumor necrosis factor (TNF) therapy, the development of PM/dermatomyositis (DM) or antisynthetase syndrome following anti-TNF therapy is extremely rare. Here, we report a case of an RA patient with anti-PL-12 antibodies, who received ETN therapy and subsequently developed the antisynthetase syndrome. She recovered when ETN therapy was withdrawn and high-dose corticosteroid was administered. To date, there have been only five reported cases of RA patients with anti-Jo-1 antibodies who developed overt PM/DM following anti-TNF therapy and only one case of antisynthetase syndrome in an RA patient with anti-PL-7 antibodies. Our patients and the abovementioned reports strongly suggest that onset of overt PM/DM or antisynthetase syndrome in RA patients with anti-aminoacyl tRNA synthetase antibodies is associated with anti-TNF therapy.
authors.affiliation: Department of Rheumatology and Clinical Immunology, Kyoto University Hospital, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan.
authors.forename: Yuki
authors.initials: Y
authors.lastname: Ishikawa
authors.forename: Naoichiro
authors.initials: N
authors.lastname: Yukawa
authors.forename: Daisuke
authors.initials: D
authors.lastname: Kawabata
authors.forename: Koichiro
authors.initials: K
authors.lastname: Ohmura
authors.forename: Takao
authors.initials: T
authors.lastname: Fujii
authors.forename: Takashi
authors.initials: T
authors.lastname: Usui
authors.forename: Tsuneyo
authors.initials: T
authors.lastname: Mimori
mesh_terms: D000604:Amino Acyl-tRNA Synthetases / Q000378:metabolism; D000888:Antibodies, Anti-Idiotypic / Q000097:blood* / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000150:complications* / Q000188:drug therapy; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D008875:Middle Aged; D009220:Myositis / Q000150:complications; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*
chemical_list: D000888:Antibodies, Anti-Idiotypic; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000604:Amino Acyl-tRNA Synthetases; D000068800:Etanercept